Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

STEPHEN J VOLK

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1598810913
CMS profile
299436
Location
PARAMOUNT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$598.80

26 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $598.80 26

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

STEPHEN J VOLK

NPI 1598810913 · CMS profile ID 299436

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

PARAMOUNT, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1598810913?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
STEPHEN J VOLK, NPI 1598810913, CMS profile ID 299436. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1598810913?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). STEPHEN J VOLK, NPI 1598810913, CMS profile ID 299436. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1598810913?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
STEPHEN J VOLK, NPI 1598810913, CMS profile ID 299436, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–26 of 26 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1598810913?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

26 matching records · $598.80 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 26 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–26 of 26.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Vanda Pharmaceuticals Inc. $16.8612/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697672653 CMS
Alkermes, Inc. $24.2412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637829 CMS
Janssen Pharmaceuticals, Inc $13.0711/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659363055 CMS
Alkermes, Inc. $24.6711/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637827 CMS
Teva Pharmaceuticals USA, Inc. $17.3510/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697796691 CMS
Sunovion Pharmaceuticals Inc. $15.2510/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047491 CMS
Lundbeck LLC $19.7110/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684369406 CMS
Otsuka America Pharmaceutical, Inc. $22.5610/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687503057 CMS
Vanda Pharmaceuticals Inc. $32.1309/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697672651 CMS
Alkermes, Inc. $24.0209/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637831 CMS
Janssen Pharmaceuticals, Inc $19.3309/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659363053 CMS
Lundbeck LLC $24.8008/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684369397 CMS
Teva Pharmaceuticals USA, Inc. $21.4408/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697778567 CMS
Alkermes, Inc. $24.3207/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637825 CMS
Janssen Pharmaceuticals, Inc $121.2906/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659363051 CMS
Janssen Pharmaceuticals, Inc $12.5706/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659363049 CMS
Alkermes, Inc. $23.5505/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637823 CMS
Alkermes, Inc. $20.4704/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637821 CMS
Janssen Pharmaceuticals, Inc $12.4303/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659363047 CMS
Sunovion Pharmaceuticals Inc. $13.6703/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047487 CMS
Sunovion Pharmaceuticals Inc. $15.0403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047489 CMS
Sunovion Pharmaceuticals Inc. $17.4002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047485 CMS
Alkermes, Inc. $20.4202/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686637819 CMS
Sunovion Pharmaceuticals Inc. $16.3201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047481 CMS
Sunovion Pharmaceuticals Inc. $11.5201/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688047483 CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. $14.3701/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 696056937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $598.80 26
PY2020 $188.51 4
PY2021 $344.69 4
PY2022 $46.91 1
PY2023 $366.72 4
PY2024 $483.65 6
PY2025 $853.47 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $606,019.12 133
PY2024 Principal investigator $514,555.10 86
PY2023 Principal investigator $208,538.60 43
PY2022 Principal investigator $558,420.91 45
PY2021 Principal investigator $274,215.89 43
PY2020 Principal investigator $1,094,352.08 67
PY2019 Principal investigator $114,933.36 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $840.00 12/31/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 (Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100764189
Principal investigator 1 ABBVIE INC. $500.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760933
Principal investigator 1 ABBVIE INC. $1,250.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760935
Principal investigator 1 ABBVIE INC. $500.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760945
Principal investigator 1 ABBVIE INC. $500.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100760947
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155300
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155304
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155308
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155312
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155320
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155324
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155328
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155332
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155336
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155339
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155343
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155347
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155351
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,670.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155354
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155358
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $106.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155362
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155366
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155370
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155374
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155377
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155381
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155385
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155389
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155392
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155396
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155400
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155404
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155408
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155412
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 12/11/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143155415
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,126.20 12/09/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUITE LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Lumateperone for the Prevention of Relapse in Patients With Schizophrenia No dispute reported 06/30/2026 1143152474
Principal investigator 1 ABBVIE INC. $40,241.38 11/29/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100757205
Principal investigator 1 ABBVIE INC. $1,131.60 11/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100756785
Principal investigator 1 ABBVIE INC. $3,048.75 11/21/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100756099
Principal investigator 1 ABBVIE INC. $82,693.75 11/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of00FFCVL-23100FF(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100754945
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $330.00 11/08/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143147432
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144650
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144653
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144657
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144660
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144664
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144668
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144672
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,954.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144675
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144679
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144683
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144687
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144691
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144694
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,831.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144698
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,240.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144702
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,879.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144706
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,696.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144710
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,990.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144713
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,595.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144717
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,400.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144721
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $88.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144725
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $51.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144729
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $51.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144732
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $40.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144736
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $40.00 11/06/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143144740
Principal investigator 1 Sumitomo Pharma America, Inc. $4,174.00 11/01/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia No dispute reported 06/30/2026 1148437812
Principal investigator 1 Sumitomo Pharma America, Inc. $1,200.00 11/01/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
An Open-label Extension Study to Assess the Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia No dispute reported 06/30/2026 1148437814
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $9,000.00 09/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143137478
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,000.00 09/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143137482
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,052.00 09/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143137485
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 09/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143137489
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,420.00 09/27/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
ITI-007-451 No dispute reported 06/30/2026 1143137493
Principal investigator 1 ABBVIE INC. $10,000.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742316
Principal investigator 1 ABBVIE INC. $18,900.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742346
Principal investigator 1 ABBVIE INC. $12,000.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742348
Principal investigator 1 ABBVIE INC. $43,200.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742350
Principal investigator 1 ABBVIE INC. $5,400.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742352
Principal investigator 1 ABBVIE INC. $5,400.00 09/13/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100742354
Principal investigator 1 ABBVIE INC. $42,533.75 08/07/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis No dispute reported 06/30/2026 1100735280
Principal investigator 1 Sumitomo Pharma America, Inc. $1,680.80 03/04/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia No dispute reported 06/30/2026 1148437816
Principal investigator 1 Sumitomo Pharma America, Inc. $5,714.00 03/01/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
An Open-Label, Fixed Sequence, Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation No dispute reported 06/30/2026 1148437820
Principal investigator 1 Sumitomo Pharma America, Inc. $50.00 01/31/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE
A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia No dispute reported 06/30/2026 1148437822
Principal investigator 1 Sumitomo Pharma America, Inc. $26,477.00 01/24/2024 Non-covered Recipient Entity
CATALINA RESEARCH INSTITUTE LLC
An Open-Label, Fixed Sequence, Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation No dispute reported 06/30/2026 1148437818
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,026.87 01/13/2024 Non-covered Recipient Entity
Catalina Research Institute LLC
BI 425809 Adjunctive Computerized Cognitive Training (CCT) No dispute reported 06/30/2026 1101070527